Picard Medical to Present Emperor Artificial Heart Data

SynCardia's Dr. Andre Simon will share first in vitro and in vivo evaluation of the Emperor Total Artificial Heart at the EUMS summit.

Published on Feb. 10, 2026

Got story updates? Submit your updates here. ›

Picard Medical, Inc., the parent company of SynCardia Systems LLC, announced that Dr. Andre Simon, Vice President of Clinical Affairs, will present data on the fully implantable Emperor Total Artificial Heart (TAH) at the upcoming 19th EUMS (European Mechanical Circulatory Support Summit) & 11th International Course on Mechanical Circulatory Support (MCS) and New Technologies in Advanced Heart Failure (HF) congress in Barcelona, Spain.

Why it matters

The Emperor TAH is a significant development in the field of artificial hearts, as it represents the next generation of total artificial heart technology. Picard Medical's presentation of the first in vitro and in vivo evaluation data for the Emperor TAH at the prestigious EUMS summit will showcase the company's technological advancements and its commitment to improving treatment options for patients with end-stage heart failure.

The details

Dr. Andre Simon will present the data on the Emperor TAH during the 'Latest Advances in Short-Term MCS and Advanced Heart Failure' session on Monday, February 16, 2026 from 17:15 to 18:15 Central European Time. The presentation is titled 'The Emperor Rises: First In Vitro and In Vivo Evaluation of SynCardia's Electromechanical Total Artificial Heart'.

  • The EUMS & 11th International Course on MCS New Technologies in HF congress will be held from February 15th to 18th, 2026 in Barcelona, Spain.
  • Dr. Andre Simon's presentation on the Emperor TAH will take place on Monday, February 16, 2026 from 17:15 to 18:15 Central European Time.

The players

Picard Medical, Inc.

The parent company of SynCardia Systems LLC, the leader in total artificial heart technology with the only commercially available total artificial heart approved by the FDA and Health Canada.

SynCardia Systems LLC

A subsidiary of Picard Medical, Inc. and the maker of the SynCardia Total Artificial Heart, the most widely used and extensively studied artificial heart in the world.

Dr. Andre Simon

The Vice President of Clinical Affairs at SynCardia Systems LLC, who will be presenting the data on the Emperor Total Artificial Heart at the EUMS summit.

Got photos? Submit your photos here. ›

What they’re saying

“The Emperor Rises: First In Vitro and In Vivo Evaluation of SynCardia's Electromechanical Total Artificial Heart”

— Dr. Andre Simon, Vice President of Clinical Affairs

The takeaway

Picard Medical's presentation of the first in vitro and in vivo data for the Emperor Total Artificial Heart at the prestigious EUMS summit highlights the company's technological advancements and its commitment to improving treatment options for patients with end-stage heart failure, a significant step forward in the field of artificial heart technology.